|
Absence of sensation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Implications of deranged activated partial thromboplastin time for anaesthesia and surgery.
|
30315725 |
2018 |
|
Acquired Immunodeficiency Syndrome
|
0.020 |
AlteredExpression
|
group |
BEFREE |
A selective defect in tissue factor mRNA expression in monocytes from AIDS patients.
|
2293902 |
1990 |
|
Acquired Immunodeficiency Syndrome
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Tissue factor (TF) is a molecular marker that is up-regulated in cancer cells and aids tumoral dissemination.
|
21128872 |
2011 |
|
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The heterozygous prothrombin G20210A variant was found together with acquired activated protein C resistance and a reduced activated partial thromboplastin time.
|
15650545 |
2005 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The following laboratory tests were performed: prothrombin time, partial thromboplastin time, fibrinogen levels, antithrombin III, plasmatic fibronectin (as a marker of endothelial damage), haptoglobin (as a marker of intravascular haemolysis), a functional test for APC-R and analysis of factor V Leiden mutation by polymerase chain reaction.
|
12571435 |
2002 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To study this, recombinant FV mutants were reconstituted in FV-deficient plasma, after which normalized APC-sensitivity ratios (n-APC-SRs) were measured in activated partial thromboplastin time-based and Russell's Viper Venom time-based APC-resistance tests.
|
11943934 |
2002 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a tissue factor-based factor V assay to detect APC resistance recently described by Le et al.
|
8990627 |
1996 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
Standard and modified partial thromboplastin time-based assays were used to evaluate response to activated protein C. A sensitivity ratio < or =2 indicated resistance to activated protein C. Repeated measures analysis of variance and unpaired t tests were used as appropriate.P <.05 was considered significant.
|
10871461 |
2000 |
|
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
|
16479199 |
2006 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Several functional tests, which are based on activated partial thromboplastin time clotting assays, are also commercially available for the detection of APC resistance.
|
9128263 |
1997 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The APC resistance phenotype was assessed by measuring the prolongation of the activated partial thromboplastin clotting time in response to APC.
|
8735142 |
1996 |
|
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results support a role for platelet turnover, factor V, and aAPCR in the thrombosis of ET as well as the association between JAK2 V617F allele burden and either decreased free PS or increased TF and soluble markers of platelet and endothelial activation.
|
19105233 |
2009 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, the association between SHBG levels and the normalized activated partial thromboplastin time-based APC resistance (an intermediate endpoint for venous thrombosis) was determined.
|
22882730 |
2012 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The activated protein C sensitivity ratio was expressed as the ratio of activated partial thromboplastin times measured in the presence and absence of activated protein C; a ratio <2.0 in patients who did not have factor V Leiden was considered to indicate acquired activated protein C resistance.
|
11165549 |
2001 |
|
Activated Protein C Resistance
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We assessed whether additional mechanisms contribute to APC resistance in a blinded case-control study of 65 subjects by measuring APC resistance using 3 methods: 2 activated partial thromboplastin time-based methods with and without dilution in factor V-deficient plasma and 1 Russell viper venom-based assay (RVV).
|
12520697 |
2003 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
|
18854273 |
2008 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.
|
23188048 |
2013 |
|
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that the aPCR-dRVVT-based test is more reliable and sensitive than the aPCR-tissue factor-based one to the R506Q mutation in patients with LAs.
|
9716147 |
1998 |
|
Activated Protein C Resistance
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently published guidelines on thrombophilia testing recommend assays for protein C, protein S and antithrombin; a modified activated protein C resistance test (with factor V-deficient plasma); polymerase chain reaction for prothrombin G20201A, together with prothrombin time, activated partial thromboplastin time, thrombin clotting time and assays to detect antiphospholipid antibodies.
|
12680634 |
2003 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
366 breast cancer patients and 307 controls were genotyped for SNPs (n = 41) in the F2, F3 (TF), F5, F7, F10, TFPI and EPCR genes, and assayed for plasma coagulation markers (thrombin generation, activated protein C (APC) resistance, D-dimer, antithrombin, protein C, protein S, and TF pathway inhibitor (TFPI)).
|
25407022 |
2014 |
|
Activated Protein C Resistance
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report three cases of recurrent venous thrombosis due not only to antiphospholipid syndrome with a normal activated partial thromboplastin time but also to resistance to activated protein C caused by the factor V Leiden mutation.
|
10769107 |
2000 |
|
acute aortic dissection
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Pulmonary static inflation with 50% xenon attenuates decline in tissue factor in patients undergoing Stanford type A acute aortic dissection repair.
|
30174885 |
2018 |
|
acute aortic dissection
|
0.020 |
Biomarker
|
disease |
BEFREE |
Preoperative PAI-1 in BALF and TF in both serum and BALF were significant factors related to the occurrence of preoperative oxygenation impairment for Stanford type-A AAD.
|
31179061 |
2019 |
|
Acute Chest Syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
In 725 patients with ACS [Fragmin and Fast Revascularization during Instability in Coronary Artery Disease II (FRISC-II) study] and 376 controls, 13 SNPs were genotyped and plasma TF measured.
|
16239598 |
2005 |
|
Acute Chest Syndrome
|
0.050 |
Biomarker
|
disease |
BEFREE |
The presence of CD3(+)-TF(+)cells was also evaluated by immunohistochemistry in thrombi aspirated from ACS-STEMI patients.
|
27236113 |
2016 |